Failure to Detect Systemic Levels, and Effects of Loteprednol Etabonate and its Metabolite, PJ-91, Following Chronic Ocular Administration
- 1 April 1998
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Journal of Ocular Pharmacology and Therapeutics
- Vol. 14 (2), 153-158
- https://doi.org/10.1089/jop.1998.14.153
Abstract
The objective of this study was to determine the systemic exposure to loteprednol etabonate (LE) following its chronic, ocular instillation. This was a randomized, double-masked, placebo controlled, single center trial in 14 normal volunteers. Subjects were randomly assigned to receive either LE (n=10) or placebo (n=4) and instructed to instill one drop into each eye 8 times daily on Days 0 and 1 and four times daily on Days 2 through 42. Blood levels of loteprednol etabonate (LE) and its major metabolite PJ-91 (delta1 cortienic acid etabonate) in plasma, and circulating plasma cortisol levels were measured during the study. Plasma levels of LE or PJ-91 were below the level of quantitation (1 ng/mL) for all subjects in both treatment groups. Plasma cortisol levels were all within the normal range. Chronic exposure to LE at a concentration and frequency equal to or greater than the intended therapeutic dose does not result in detectable systemic levels or hypothalamic pituitary axis suppression.Keywords
This publication has 5 references indexed in Scilit:
- A Double-masked, Placebo-controlled Evaluation of the Efficacy and Safety of Loteprednol Etabonate in the Treatment of Giant Papillary ConjunctivitisAmerican Journal of Ophthalmology, 1997
- Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyesCurrent Eye Research, 1991
- Soft drugs: Principles and methods for the design of safe drugsMedicinal Research Reviews, 1984
- Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphateCurrent Eye Research, 1984
- Cushing's syndrome: A review of diagnostic testsMetabolism, 1979